Alts Watch Healthcare Beat: $1.1bn supporting novel therapies, T-cell research

New treatments for cancer, rheumatoid arthritis and diabetes are on the horizon thanks to a series private capital deals over the past week.

Alternative investment firms leading the way were: H.I.G. Capital; BlackRock; Surveyor Capital (a Citadel company); New Enterprise Associates; Deerfield Management and Bain Capital Life Sciences.

Below is our weekly run-down of all healthcare-oriented deals $40 million and up for the week ending January 31.

BridgeBio Pharma

  • The deal: $400 million in convertible senior notes.
  • The players: Aiming to attract . . .

    Continue Reading

    Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

    Get started

Back to top button

Get our daily news digest
in your inbox

Our FREE mailing list brings you daily alts intel.

Thank you for subscribing.

Something went wrong.